European Crohn's and Colitis Organisation (J Crohns Colitis)
Guideline
Oct 2024
For professionals
Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.
Topics
Medicines
Biologics and newer medicines
Immunosuppressants
Around the bottom (perianal)
Jargon explained
biologic
immunomodulator
induction
maintenance
de-escalation
perianal fistula
GRADE
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Feb 2021
For professionals
European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.
Topics
Children and young people
Medicines
Diet and nutrition
Biologics and newer medicines
Jargon explained
paediatric
penetrating disease
stricturing disease
exclusive enteral nutrition
anti-TNF
immunomodulator
therapeutic drug monitoring
The Lancet Gastroenterology & Hepatology
Study
May 2024
Patients and professionals
A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.
Topics
Biologics and newer medicines
Research
About Crohn's disease
Jargon explained
top-down treatment
step-up treatment
biomarker
steroid-free remission
top-down
step-up
immunomodulator
randomised controlled trial
The Lancet Gastroenterology & Hepatology
Study
Oct 2020
Patients and professionals
A longer look back at the people in the LIR!C trial. It supported keyhole removal of the end of the small bowel as a real option for people with short, mainly inflamed (not narrowed) disease when standard medicines have not worked. In both groups, adding an immunosuppressant was linked to the benefit lasting longer.
Topics
Surgery
Biologics and newer medicines
Jargon explained
retrospective
hazard ratio
immunomodulator
Cochrane
Systematic review
Aug 2014
Patients and professionals
Looks at methotrexate for Crohn's that has not settled with other treatment. The trials of methotrexate by mouth were small, and adding methotrexate to infliximab did not seem to add benefit, though those studies were small too. More research is needed.
Topics
Immunosuppressants
Jargon explained
refractory
methotrexate
immunomodulator
Cochrane (via PMC)
Systematic review
Nov 2023
Patients and professionals
A Cochrane review finding infliximab combined with azathioprine or mercaptopurine probably works better than either thiopurine alone for bringing Crohn's into remission. Infliximab may work similarly to its CT-P13 biosimilar.
Topics
Biologics and newer medicines
Research
Jargon explained
combination therapy
purine analogue
biosimilar
CT-P13
Crohn's & Colitis UK
Guide
Jun 2024
For patients
A detailed guide to the thiopurine medicines azathioprine (Imuran, Jayempi) and mercaptopurine (6-MP). It explains how they work, how well they worked in trials, the TPMT enzyme test before starting, the regular blood tests needed throughout treatment, and possible side effects.
Topics
Immunosuppressants
Medicines
Monitoring
Jargon explained
thiopurine
TPMT
6-MP
bone marrow
immunosuppressant
New England Journal of Medicine
Study
Apr 2010
Patients and professionals
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics
Biologics and newer medicines
Immunosuppressants
Research
Jargon explained
combination therapy
steroid-free remission
mucosal healing
randomised controlled trial
Cochrane
Systematic review
Oct 2015
Patients and professionals
Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.
Topics
Immunosuppressants
Research
Jargon explained
thiopurine
low-quality evidence
adverse event
remission
placebo
systematic review
Gateshead Health NHS Foundation Trust
Leaflet
Dec 2024
For patients
A hospital leaflet explaining in simple terms how azathioprine and mercaptopurine weaken the immune system so it stops attacking the gut, how they are taken, side effects, and the schedule of blood tests, which are frequent at first and then less often.
Topics
Immunosuppressants
Monitoring
Jargon explained
immunosuppressant
thiopurine
blood monitoring
Frontline Gastroenterology (via PMC)
Guide
Nov 2025
For professionals
A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.
Topics
Medicines
Surgery
Monitoring
Jargon explained
top-down
step-up
therapeutic drug monitoring
ileocaecal resection
Rutgeerts score
immunogenicity
Cochrane
Systematic review
Aug 2019
Patients and professionals
Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.
Topics
Immunosuppressants
Surgery
Research
Jargon explained
postoperative recurrence
low certainty evidence
post-operative recurrence
thiopurine
5-ASA
anti-TNF